The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern US

被引:4
|
作者
Van Gerwen, Olivia T. [1 ]
Yigit, Ibrahim [2 ]
Crockett, Kaylee B. [3 ]
Turan, Bulent [4 ,5 ]
机构
[1] Univ Alabama Birmingham, Div Infect Dis, 703 19th St South,ZRB 218A, Birmingham, AL 35233 USA
[2] TED Univ, Fac Arts & Sci, Dept Psychol, Ankara, Turkey
[3] Univ Alabama Birmingham, Dept Family & Community Med, Birmingham, AL USA
[4] Koc Univ, Coll Social Sci & Humanities, Dept Psychol, Istanbul, Turkey
[5] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA
基金
美国国家卫生研究院;
关键词
HIV pre-exposure prophylaxis; Adherence; Stigma; PrEP; TENOFOVIR DISOPROXIL FUMARATE; INTERNALIZED STIGMA; PREVENTION; MECHANISMS; INFECTION; EFFICACY; PEOPLE; SCALE; RISK; PREP;
D O I
10.1007/s10461-022-03883-3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Despite efficacy in HIV prevention, Pre-exposure Prophylaxis (PrEP) is underutilized in the US, especially among populations at highest risk. PrEP-related stigma may play a role. We developed measures of PrEP-related stigma dimensions and PrEP adherence. We administered them to current PrEP users. We hypothesized that PrEP-related stigma would negatively impact PrEP adherence. Questionnaire measures were developed using data from previous qualitative work and existing validated HIV-related stigma measures. The resultant survey was administered to current PrEP users from two Birmingham, Alabama PrEP clinics. Plasma tenofovir disoproxil fumarate levels were collected to measure PrEP adherence. Exploratory factor analyses were performed to determine the factor structure of each PrEP-related stigma dimension (internalized, perceived, experienced, anticipated, disclosure concerns). Separate binary logistic (or linear) regressions were performed to assess associations between PrEP-related stigma dimensions and adherence (treatment adherence self-efficacy, self-reported adherence, and plasma tenofovir levels), adjusting for education, race, and time on PrEP. In 2018, 100 participants completed the survey, with 91 identifying as male and 66 as white. Only internalized stigma was associated with lower self-reported PrEP adherence. Exploratory mediation analyses suggested that the association between all stigma dimensions and self-reported PrEP adherence is mediated by PrEP adherence self-efficacy. No associations were found between any PrEP-related stigma measures and plasma tenofovir levels. Internalized PrEP stigma may reduce PrEP adherence, possibly by reducing PrEP adherence self-efficacy among experienced PrEP users. Further investigation of how stigma dimensions affect PrEP adherence in populations at risk for HIV may shed light on drivers of PrEP underutilization.
引用
收藏
页码:1478 / 1485
页数:8
相关论文
共 50 条
  • [21] Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection
    Gengiah, Tanuja N.
    Moosa, Atika
    Naidoo, Anushka
    Mansoor, Leila E.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2014, 36 (01) : 70 - 85
  • [22] Experiences of Pre-Exposure Prophylaxis Stigma, Social Support, and Information Dissemination Among Black and Latina Transgender Women Who Are Using Pre-Exposure Prophylaxis
    Brooks, Ronald A.
    Cabral, Alejandra
    Nieto, Omar
    Fehrenbacher, Anne
    Landrian, Amanda
    TRANSGENDER HEALTH, 2019, 4 (01) : 188 - 196
  • [23] Willingness to Use HIV Pre-Exposure Prophylaxis Among Opiate Users
    Michael Stein
    Portia Thurmond
    Genie Bailey
    AIDS and Behavior, 2014, 18 : 1694 - 1700
  • [24] Antiretroviral Drugs for Pre-Exposure Prophylaxis of HIV Infection
    Vicente Fernandez-Montero, Jose
    Barreiro, Pablo
    del Romero, Jorge
    Soriano, Vincent
    AIDS REVIEWS, 2012, 14 (01) : 54 - 61
  • [25] SOCIAL JUDGMENTS OF SEXUAL BEHAVIOR AND USE OF HIV PRE-EXPOSURE PROPHYLAXIS
    Martinez, Joel E.
    Jonas, Kai J.
    SOCIAL COGNITION, 2020, 38 (01) : 1 - 20
  • [26] Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection
    Tanuja N. Gengiah
    Atika Moosa
    Anushka Naidoo
    Leila E. Mansoor
    International Journal of Clinical Pharmacy, 2014, 36 : 70 - 85
  • [27] Understanding Retention in the HIV Pre-Exposure Prophylaxis Cascade Among Cisgender Women
    Burns, Jamie A. A.
    Hull, Shawnika J. J.
    Inuwa, Aisha
    Moriarty, Patricia
    Scott, Rachel K. K.
    AIDS PATIENT CARE AND STDS, 2023, 37 (04) : 205 - 211
  • [28] HIV pre-exposure prophylaxis in women
    Haberl A.
    MMW - Fortschritte der Medizin, 2017, 159 (Suppl 2) : 42 - 44
  • [29] Oral pre-exposure prophylaxis for HIV prevention
    Garcia-Lerma, J. Gerardo
    Paxton, Lynn
    Kilmarx, Peter H.
    Heneine, Walid
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (02) : 74 - 81
  • [30] A Systematic Review of Oral Pre-exposure Prophylaxis HIV Adherence Interventions
    Haines, Marlene
    Vandyk, Amanda
    Skidmore, Becky
    Orser, Lauren
    O'Byrne, Patrick
    JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2024, 35 (04): : 309 - 324